Therapeutic activity of a new KRASG12C inhibitor JMKX001899 in brain metastases: Preclinical models of KRASG12C-mutant non-small cell lung cancer

被引：0
|
作者：
He, Danming
Wang, Jie
Zhu, Yixiang
Zhong, Jia
Bai, Hua
机构：
[1] Chinese Acad Med Sci, State Key Lab Mol Oncol, CAMS Key Lab Translat Res Lung Canc,Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc,Dept Med Onc, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp,State Key Lab Mo, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8630
引用
收藏
页数：1
相关论文
共 50 条
  • [31] WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Saito, Hitoshi
    Yamamori-Morita, Tomoko
    Nakao, Takehiro
    Liu, Jie
    Mori, Shunta
    Yagishita, Shigehiro
    Hamada, Akinobu
    Shinno, Yuki
    Yoshida, Tatsuya
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-Ichi
    Yatabe, Yasushi
    Kitai, Hidenori
    Konno, Satoshi
    Kobayashi, Susumu S.
    Ohashi, Akihiro
    CANCER LETTERS, 2025, 611
  • [32] First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation
    De, Surya K.
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (03) : 266 - 272
  • [33] Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer
    Ghazi, Phaedra
    O'Toole, Kayla
    Boggaram, Sanjana
    Scherzer, Michael
    Bogdan, Madhumita
    Smith, Bryan
    Flynn, Dan
    Kinsey, Conan
    McMahon, Martin
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Proteomic and transcriptomic subtypes of KRASG12c mutant lung cancer.
    Solanki, Hitendra Singh
    Stewart, Paul A.
    Welsh, Eric A.
    Izumi, Victoria
    Fang, Bin
    Yoder, Sean J.
    Koomen, John M.
    Haura, Eric B.
    CANCER RESEARCH, 2022, 82 (12)
  • [35] KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
    Fujimoto, Kazushi
    Ikeda, Satoshi
    Tabata, Erina
    Kaneko, Taichi
    Sagawa, Shinobu
    Yamada, Chieri
    Kumagai, Kosumi
    Fukushima, Takashi
    Haga, Sanshiro
    Watanabe, Masayuki
    Muraoka, Tatsuya
    Sekine, Akimasa
    Baba, Tomohisa
    Ogura, Takashi
    CANCERS, 2024, 16 (07)
  • [36] A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models
    Ying, Haiyan
    Guo, Fushen
    Peng, Juan
    Wang, Jie
    Zhang, Jie
    Liu, Manqi
    Zhu, Zhixuan
    Chen, Zhui
    CANCER RESEARCH, 2023, 83 (08)
  • [37] Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.
    May, Michael S.
    Wooster, Margaux
    May, Benjamin
    Shu, Catherine A.
    Henick, Brian S.
    Stoopler, Mark
    Smith-Marrone, Stephanie
    Saqi, Anjali
    Mansukhani, Mahesh M.
    Riely, Gregory J.
    Hershman, Dawn L.
    Herzberg, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer
    Sayama, Hiroyuki
    Marcantonio, Diana
    Nagashima, Takeyuki
    Shimazaki, Masashi
    Minematsu, Tsuyoshi
    Apgar, Joshua F.
    Burke, John M.
    Wille, Lucia
    Nagasaka, Yasuhisa
    Kirouac, Daniel C.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 864 - 877
  • [39] The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
    Patel, Hetika V.
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [40] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Torres-Jimenez, Javier
    Espinar, Javier Baena
    de Cabo, Helena Bote
    Berjaga, Maria Zurera
    Esteban-Villarrubia, Jorge
    Fraile, Jon Zugazagoitia
    Paz-Ares, Luis
    DRUGS, 2024, 84 (05) : 527 - 548
12345